CrossRef Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients David Prez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hlne Borges, Salom Biennier, Marie Couron, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Cout, Christophe Bru Biomarker Research .2024;[Epub] CrossRef Aspartate Aminotransferase to Platelet Ratio Index (APRI) as a Predictor of Metabolic Syndrome (MetS) Development in Individuals With Type 2 Diabetes Mellitus Amir Jalisi, Rijad Jahi, Avdo Kurtovi, Miralem eevi, Azra Husi-Selimovi, Enisa Hodi, Edina Lazovi Salin, Orhan Lepara, Almir Fajki Cureus .2024;[Epub] CrossRef Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Mohammadjavad Sotoudeheian Protein & Peptide Letters .2024

Different metabolic processes and reprogramming unique to each phase have been described and play a role in the different, varied clinical manifestations in the two phases
Its been two days since 1st dose of Pfizer and Im also having a light burning sensation in my chest similar to heartburn
Kizilkaya V, Uruc V, Levent A, Kanat O, Yildizgoren MT, Dogramaci Y, et al